IRVINE, Calif., March 5 /PRNewswire/ -- Numira Biosciences announced the appointment of Paul Grint, M.D., to its Board of Directors.
Currently, Dr. Grint serves as the Chief Medical Officer and Head of Development at Kalypsys, Inc., a drug discovery and development company based in San Diego, CA. Prior to Kalypsys, he held senior management positions at Zephyr Sciences, Pfizer Global Research & Development, IDEC Pharmaceuticals, and Schering-Plough. Additionally, he is a member of the Board of Directors at Illumina Inc. and serves as Chairman of the Advisory Council of the Keck Graduate Institute.
"We are very pleased to have attracted an industry leader of Dr. Grint's caliber," said Michael Beeuwsaert, President and CEO of Numira. "His extensive background in drug discovery and development will be invaluable to us as we head into our next phase of growth."
About Numira Biosciences
Numira Biosciences is a specialty R&D tools company focused on leveraging advances in genetics and molecular imaging to create a catalog of novel, high-value products that provide researchers with unprecedented insight into genomics, developmental biology, mechanisms of disease, drug efficacy, and toxicity.
For more information, please visit the company's website at http://www.numirabio.com.
CONTACT: Michael Beeuwsaert, President & CEO of Numira Biosciences Inc.,
+1-949-567-0920, mbeeuwsaert@numirabio.com
Web site: http://www.numirabio.com/
